Organization | Braintree Laboratories

Braintree Laboratories Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4

Founded: Braintree MA United States (1982)

Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial

1999

NCT00164164

First Marketed Drug

1984

potassium chloride (klor-con)

First NDA Approval

1984

sodium sulfate

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

BRAINTREE | Braintree Laboratories | Braintree Laboratories, Inc. | BRAINTREE LABS

Active Ingredients

Marketed Drugs (11)

alcaftadine (Lastacaft) (2010)

bisacodyl (Halflytely) (2004)

lactitol (Pizensy) (2020 NDA)

magnesium sulfate (Tis-U-Sol) (2010)

nizatidine (axid) (2004)

polyethylene glycol (1984)

potassium chloride (klor-con) (1984)

potassium sulfate (2010 NDA)

sodium bicarbonate (1984)

sodium chloride (1984)

sodium sulfate (1984 NDA)

Drugs in Phase 4 Trials (5)

bisacodyl (Halflytely) (5 trials)

magnesium oxide (1 trial)

polyethylene glycol (26 trials)

potassium (1 trial)

sodium sulfate (11 trials)

Drugs in Phase 3 Trials (11)

bli400 (4 trials)

bli-801 (5 trials)

human fecal microbiota (Reybota) (2 trials)

lansoprazole (prevacid) (3 trials)

loperamide (imodium) (2 trials)

lubiprostone (amitiza) (1 trial)

magnesium sulfate (Tis-U-Sol) (5 trials)

nizatidine (axid) (1 trial)

potassium sulfate (5 trials)

sodium phosphate (1 trial)

sucralose (2 trials)

Drugs in Phase 2 Trials (3)

bli1100 (3 trials)

bli-1300 (1 trial)

erdafitinib (Balversa) (1 trial)

Indications

Approved Indications

Conjunctivitis, Allergic

Experimental Indications (Clinical Trials, Phases 1-4)

Acne Vulgaris (Phase 2)

Colonic Neoplasms (Phase 3)

Constipation (Phase 4)

Crohn Disease (Phase 2)

Esophagitis, Peptic (Phase 3)

Gastroesophageal Reflux (Phase 3)

Heartburn (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 49
# of Trial APIs: 19